echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Preventive treatment of Nirsevimab can reduce the risk of RSV-related respiratory infections in premature babies.

    NEJM: Preventive treatment of Nirsevimab can reduce the risk of RSV-related respiratory infections in premature babies.

    • Last Update: 2020-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in infants, and researchers recently examined the effects of a single Nirsevimab monoimmune injection on the risk of infection in infants throughout the RSV epidemic season.
    the study, the researchers assessed the effects of Nirsevimab on RSV-related lower respiratory tract infections in premature and healthy newborns (29 weeks to 34 weeks 6 days).
    before the start of the RSV epidemic season, the study involved newborns receiving a single intramuscular injection of 50 mg of Nirsevimab or a placebo. The main endpoint of the
    study was a 150-day medical intervention for RSV-related lower respiratory tract infections.
    secondary efficacy endpoint was 150 days of hospitalization for RSV-related lower respiratory tract infections.
    from November 2016 to November 2017, a total of 1,453 infants participated in the study and received Eirsevimab (n-969) or a placebo (n?484) before the RSV pandemic.
    statistics found that the incidence of RSV-related lower respiratory tract infections requiring internal medicine in the Nirsevimab group was 70.1% lower than in the placebo group (2.6% vs 9.5%).
    the hospitalization rate of RSV-related lower respiratory tract infections after preventive treatment in Nirsevimab decreased by 78.4% (0.8% vs 4.1%, P-lt;0.001) compared to the placebo group.
    had similar adverse reactions between the groups and had no apparent allergic reactions.
    single injection of Nirsevimab throughout the RSV epidemic season reduces the risk of RSV-related respiratory infections and hospitalization in healthy premature infants.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.